| Identification | Back Directory | [Name]
CKZHFOKQZRZCPF-ROUUACIJSA-N | [CAS]
791826-72-7 | [Synonyms]
INCB3619
INCB-3619
INCB 3619
CKZHFOKQZRZCPF-ROUUACIJSA-N | [Molecular Formula]
C22H27N3O5 | [MDL Number]
MFCD28411422 | [MOL File]
791826-72-7.mol | [Molecular Weight]
413.467 |
| Hazard Information | Back Directory | [Uses]
INCB3619 is a selective and orally active ADAM inhibitor with IC50 of 22 nM and 14 nM for ADAM10 and ADAM17, respectively. INCB3619 has anti-tumor activity[1]. | [in vivo]
INCB3619 (subcutaneous injection, 60 mg/kg/d, 14 d) exhibits antitumor activity and sensitizes tumors to Gefitinib (HY-50895) in A549 xenografted BALB/c nu/nu mouse model[1].
| Animal Model: | BALB/c nu/nu mouse model of A549 xenograft | | Dosage: | 50, 60 mg/kg | | Administration: | subcutaneous injection, daily, 14 d | | Result: | Significant tumor growth inhibition and delay at 60 mg/kg dose, less active effect at 50 mg/kg. |
| [References]
[1] Bin-Bing S Zhou, et al. Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer. Cancer Cell. 2006 Jul;10(1):39-50. DOI:10.1016/j.ccr.2006.05.024 |
|
|